

REG gene expression in inflamed and healthy colon mucosa explored by in situ hybridisation

Atle van Beelen Granlund · Ann Elisabet Østvik · Øystein Brenna · Sverre H. Torp · Bjørn I. Gustafsson · Arne Kristian Sandvik

Received: 10 December 2012 / Accepted: 14 February 2013 / Published online: 22 March 2013

© The Author(s) 2013. This article is published with open access at Springerlink.com

Abstract The regenerating islet-derived (REG) gene family encodes a group of proteins highly expressed in several human pathologies, many of which are associated with epithelial inflammation. All human family members, namely *REG1A*, *REG1B*, *REG3A* and *REG4*, are closely related in genomic sequence and all are part of the c-type lectin superfamily. REGs are highly expressed during inflammatory bowel disease (IBD)-related colonic inflammation and the in vivo expression pattern of *REG1A* and *REG4* has been localised by using immunohistochemistry. However, the function of the encoded proteins is largely unknown and the cellular localisation of *REG* expression during colonic inflammation has not been described. Therefore, we have

used in situ hybridisation to demonstrate the cellular localisation of *REG* expression in healthy and diseased colonic mucosa. Samples drawn from an IBD cohort including both inflamed and un-inflamed colonic mucosa are described, as are samples from non-IBD inflammation and healthy controls. Immunohistochemistry against known cell-type markers on serial sections has localised the expression of REGs to metaplastic Paneth cells (*REG1A*, *REG1B* and *REG3A*) and enteroendocrine cells (*REG4*), with a marked expansion of expression during inflammation. The group of REGs can, based on gene expression patterns, be divided into at least two groups; *REG1A*, *REG1B* and *REG3A* with their expression focused in the crypt base spreading from Paneth cells and *REG4* being more highly expressed towards the luminal face. This exploration of expression pattern forms provides the background for further exploration of REG function in the intestine.

Electronic supplementary material The online version of this article (doi:10.1007/s00441-013-1592-z) contains supplementary material, which is available to authorized users.

A. van Beelen Granlund · A. E. Østvik · A. K. Sandvik
Centre of Molecular Inflammation Research, Norwegian
University of Science and Technology, Trondheim, Norway

A. van Beelen Granlund · A. E. Østvik · Ø. Brenna ·
B. I. Gustafsson · A. K. Sandvik (✉)
Department of Cancer Research and Molecular Medicine,
Norwegian University of Science and Technology, P.O. Box 8905,
7491 Trondheim, Norway
e-mail: arne.sandvik@ntnu.no

S. H. Torp
Department of Laboratory Medicine, Norwegian University
of Science and Technology, Trondheim, Norway

A. E. Østvik · Ø. Brenna · B. I. Gustafsson · A. K. Sandvik
Department of Gastroenterology and Hepatology, St. Olav's
University Hospital, Trondheim, Norway

S. H. Torp
Department of Pathology and Medical Genetics, St. Olav's
University Hospital, Trondheim, Norway

Keywords Inflammatory bowel disease · Colitis · In situ hybridisation · Immunohistochemistry · Antimicrobial peptides · *REG* gene family · Human

Introduction

Since the discovery of the regenerating islet-derived (*REG*) gene family in connection with islet regeneration after experimental injury to rat pancreas, several studies have explored the possible functions and expression patterns of the various genes in the family. In the beginning, these studies focused mainly on the role of *REG* in ailments affecting the pancreas, such as diabetes, acute pancreatitis and pancreatic cancer. Today, we know that *REG* family proteins are highly expressed in the epithelial lining of many organs in connection with tissue injury and inflammation.

In humans, the *REG* gene family currently consists in four well-established members: *REG1A*, *REG1B*, *REG3A* and *REG4*. All are found encoded in tandem on chromosome 2p12, except for *REG4*, which is found on 1p12. The intron-exon arrangement of all *REGs* are similar, again except for *REG4*, which has considerably longer intronic sequences (Zelensky and Gready 2005). The protein sequence suggests similarities to the C-dependent lectins, although the carbohydrate-binding motif of the *REGs* does not display the calcium-binding site common for other members of the superfamily. Our current knowledge of human *REG* protein function and its expression pattern have recently been reviewed by Parikh et al. (2012).

The suggested functions of the various *REGs* are many and surprisingly diverse, given the great similarity in the sequence of the members. Of the human *REGs*, *REG1A*, *REG3A* and *REG4* are the best studied. All *REGs* are expressed in the pancreas and small intestine, whereas only *REG4* is constitutively expressed in colon epithelia (Zhang et al. 2003). During epithelial disease, in either pancreatitis or inflammation of the bowel, the expression of *REGs* increases. Both high *REG4* and *REG1A* expression has been linked to poor prognosis in colorectal cancer (Astrosini et al. 2008; Oue et al. 2007) and both have been shown to have either a trophic or an anti-apoptotic effect. The effect of *REG4* has been further investigated by using cancer cell lines and the results suggest that *REG4* can stimulate both cell migration and proliferation (Guo et al. 2010; Rafa et al. 2010). Sekikawa et al. (2010) have demonstrated that the increase in *REG1A* expression seen in inflamed colonic mucosa correlates with *IL22* expression and is stimulated in a *STAT3*-dependent manner. An antimicrobial effect has been demonstrated for murine *Reg3g* and human *REG3A* and is possibly specific for membrane-bound peptidoglycans of Gram-positive bacteria (Cash et al. 2006).

REG1A, *REG1B*, *REG3A* and *REG4* all show increased expression during inflammatory bowel disease (IBD)-related inflammation of the colon (Dieckgraefe et al. 2002; Granlund et al. 2011; Lawrance et al. 2001). IBD is a group of chronic diseases affecting as many as 2.2 million Europeans and 1.4 million US citizens (Loftus 2004). The two main IBD subtypes, ulcerative colitis (UC) and Crohn's disease (CD), are clinically distinct. They do, however, share many features such as chronic mucosal inflammation and epithelial injury. Despite the initial discovery of the high expression of *REGs* during IBD inflammation, few studies have investigated their expression pattern in the inflamed bowel mucosa. Dieckgraefe et al. (2002) have described *REG1A* in IBD by using immunohistochemistry (IHC); the protein is expressed by metaplastic Paneth cells of the inflamed colonic mucosa. In a comprehensive study by Oue et al. (2005), the expression patterns of *REGIV* (*REG4*) in many neoplastic and non-neoplastic tissues have been

determined, with *REG4* protein expression in normal colonic tissue being shown to be limited to enteroendocrine cells.

In a previous study, we have found *REG* mRNAs to be strongly up-regulated during inflammation of the colon. We have further examined, using IHC, the expression pattern of *REG1A* and *REG4* in both in the un-inflamed and inflamed colonic mucosa from UC and CD patients, in normal colonic mucosa and in inflamed mucosa from patients with non-IBD antibiotic-induced pseudomembranous colitis (PC; Granlund et al. 2011). Whereas no *REG1A* expression is seen in normal mucosa, the Paneth cells found both in un-inflamed and inflamed IBD tissue and in inflamed tissue from patients with PC express *REG1A* protein. *REG4* has been seen in serotonin-positive cells in all colonic samples. During inflammation, the expression of both *REG1A* and *REG4* shifts to include all other epithelial cells of the colonic crypts, with expression for *REG4* increasing towards the lumen and for *REG1A* increasing towards the crypt base.

Present knowledge of the mRNA expression patterns of the various *REGs* in human colonic mucosa is extremely limited, with only a few studies demonstrating the expression of *REG1A* and *REG4* in colorectal cancer and pseudomyxoma peritonei of the appendix (Astrosini et al. 2008; Heiskala et al. 2006). In the present study, we have utilised an in situ hybridisation (ISH) method involving branched-chain DNA technology, enabling us, for the first time, to localise all human *REGs* in normal and inflamed colon. Protein expression has been studied with regard to the *REGs* for which antibodies are available. The expression pattern has been further investigated by identifying cell types expressing the various *REGs* by using IHC against appropriate cell-type markers in serial sections. The current study represents a comprehensive evaluation of *REG* expression pattern in the healthy and inflamed colon and will provide the necessary background information in further research on the regulation and function of these intriguing peptides.

Materials and methods

Samples

Sample material was drawn from a research biobank of IBD samples at St. Olav's University Hospital, except for samples of PC, which were taken from the clinical files at the Department of Pathology, St. Olav's University Hospital. Samples for IHC, ISH and microarray analysis were prepared as described previously (Granlund et al. 2011). In total, six groups of samples were defined: normal mucosa from healthy individuals (N), un-inflamed mucosa from the hepatic flexure (HF) in UC patients (UCU), un-inflamed

mucosa from HF in CD patients (CDU), inflamed colonic mucosa from UC patients (UC), inflamed colonic mucosa from CD patients (CD) and inflamed mucosa from PC patients (PC). For the IBD samples and normal controls, the procedure was as follows (in brief). Four samples from the same area were collected from each patient by pinch biopsy during colonoscopy. Three were snap-frozen and further stored in liquid nitrogen, with one biopsy being fixed in formalin and subsequently embedded in paraffin. All un-inflamed biopsies from IBD patients and normal samples from healthy controls were taken from the hepatic flexure. Diseased samples were taken from areas in which the mucosa was macroscopically maximally inflamed. Hematoxylin-eosin (H-E)-stained sections from all samples were evaluated by an expert pathologist for verification of the diagnosis. Samples for which microscopic evaluation diverged from the initial endoscopic diagnosis were removed from the sample pool. Informed written consent was obtained from all study participants. The study was approved by The Regional Medical Research Ethics Committee (no. 5.2007.910) and was registered in the Clinical Trials Protocol Registration System (identifier NCT00516776).

Microarray gene expression analysis

Samples were prepared and data were analysed as described previously (Granlund et al. 2011). In brief, all RNA samples were controlled for RNA integrity and purity. Samples not fulfilling the quality requirements were removed prior to microarray analysis. In addition to the technology-specific quality controls supplied by Illumina, two samples were used as technical controls. One of these samples was hybridised to each 12-plex chip in order to detect any deviation in results. All data from the microarray analysis were analysed by using Bioconductor in the R statistical computing environment (Gentleman et al. 2004). In short, data were log-transformed and quantile-normalised and differential expression was identified by using limma linear regression (Smyth 2005). All *P*-values were corrected for multiple comparisons by using the Benjamini-Hochberg correction. The significance level was set to a corrected *P*-value of <0.05. All data from this analysis are available in ArrayExpress E-MTAB-184. A verification of the

observed regulation of *REG* family genes by quantitative reverse transcription plus the polymerase chain reaction is given in a previous publication by Granlund et al. (2011).

Histological and immunohistological examination

Paraffin-embedded samples were cut into sections of 4 μm in thickness and mounted on glass slides. Three PC samples and five samples from each IBD sample group and normal controls were randomly selected. One section from each sample was stained with H-E for the evaluation of inflammatory status by an experienced pathologist. From each group, two samples displaying good crypt morphology were selected based on the evaluation of H-E-stained sections. These samples then formed the basis for the further evaluation of *REG* expression. This process was repeated twice, giving a total number of evaluated colonic samples of 12. The images shown in Results are all based on the six samples given in Table 1. For IHC and ISH, sequential pairs of sections were mounted with adjoining sides facing up in order to optimise serial section staining. Antibodies for REG1A (cat. no. RD181078100, BioVendor, Midrice, Czech Republic; dilution 1:500), REG4 (REGIV, cat. no. AF1379, R&D Systems, Minneapolis, Minn., USA; dilution 1:400), REG3A (cat. no. AB134209, Abcam, Cambridge, UK; dilution 1:100), Defensin alpha 6 (DEFA6, cat. no. HPA019462, Sigma, St. Louis, Mo., USA; dilution 1:1000) and serotonin (5HT, cat. no. AB16007, Abcam; dilution 1:200) were all commercially available. REG1A, REG3A, DEFA6 and serotonin were detected by using the Dako EnVision peroxidase kit (Dako, Glostrup, Denmark), whereas REGIV (REG4) was detected by using the Vectastain ABC kit (Vector Laboratories, Burlingame, Calif., USA). Dako DAB+ (diaminobenzidine) was used as the chromogene for all IHC, with all sections being counterstained with hematoxylin. Samples were de-paraffinised in Neo-Clear (Merck Millipore, Darmstadt, Germany) and antigen retrieval was performed by boiling sections in either sodium citrate (pH 6.0) or TRIS-EDTA (pH9.0) buffer for 15 min. For ISH of *REG1A*, *REG1B*, *REG3A*, *REG4* and *Chromogranin A* (*CgA*), the RNAscope 2.0 single-plex hybridisation system (Advanced Cell Diagnostics, Hayward, Calif., USA) was used according to the manufacturer's recommendations. This

Table 1 Patient characteristics (*N* normal, *UC* ulcerative colitis, *CD* Crohn's disease, *PC* pseudomembranous colitis)

Diagnosis (sample ID)	Inflammatory status	Sample Area	Sex	Age (years)
N (205 F)	Un-inflamed	Hepatic flexure	Male	51
UC (147 F)	Un-inflamed	Hepatic flexure	Male	37
CD (212 F)	Un-inflamed	Hepatic flexure	Male	42
UC (122 S)	Inflamed	Sigmoid	Female	47
CD (212 S)	Inflamed	Sigmoid	Male	42
PC (23590)	Inflamed	Splenic flexure	Male	71

method utilises branched-chain DNA technology to ensure good specificity and sensitivity (Player et al. 2001). In brief, tissue sections were heated (1 h, 60 °C) prior to deparaffinisation and rehydration, followed by a protease treatment (30 min, 42 °C in a humidifying chamber). Each slide was hybridised with target probe for 1 h at 40 °C, followed by a series of specific signal amplification steps as described in the manufacturer's protocol and was stained for 10 min by using DAB provided by the manufacturer. All sections were counterstained with hematoxylin. Initial hybridisation for each probe was performed including positive and negative controls in order to ensure proper target probe specificity. Control probes were provided by Advanced Cell Diagnostics. Positive controls targeted ubiquitin C, whereas negative control probes targeted bacterial dapB. All samples used in the final analysis performed as expected when hybridised with positive and negative control probes. Examples of positive and negative controls are given in Fig. S1.

All images were acquired by using NIS-Elements BR ver. 3.00 (Nikon Instruments, Melville, N.Y., USA). The white balance was automatically adjusted for each picture by means of the routines provided. Images were saved as TIFF-files. Subsequent image orientation and cropping was used to ease interpretation of serial sections.

Results

Samples

After evaluation of morphology, two samples from each group were selected for initial ISH. Fixation time for the samples varied and was unknown. As fixation time influences ISH strongly, this initial analysis was performed to ensure compatibility of the sample with the ISH protocol. The samples showing consistent results were used in the subsequent analysis. Sample information is given in Table 1. All samples used in the final analysis were tested with positive and negative control probes supplied by the

manufacturer of the ISH kit. Quality controls showed minimal un-specific binding of the negative control probe and good hybridisation of the positive control probe. The analysis was repeated twice with separate sets of samples in order to confirm findings.

Microarray analysis

Results from the full microarray gene expression analysis have been described in previous publications (Granlund et al. 2011). All *REG* mRNAs were potently regulated in inflamed mucosa from UC and CD and were among the top eight differentially expressed genes for the contrast UC vs. N. The analysis did not show significant regulation of *REG* genes in un-inflamed samples but a subset of samples showed an expression level similar to that seen in inflamed samples.

For the present study, the *REG* expression levels for the randomly selected samples used in IHC/ISH analysis were extracted from the full set of microarray results. The LOG2 expression levels of the present samples are given in Table 2. The normal control had *REG* levels close to background, except for *REG4*, which displayed a basal expression slightly over background. The CDU sample exhibited a slight increase in the expression of all *REGs*, whereas the UCU sample had expression levels similar to inflamed samples thereby reflecting the dichotomous distribution of *REG* expression in un-inflamed IBD samples.

ISH and IHC analyses

Normal samples showed no ISH staining for *REG1A*, *REG1B* and *REG3*. For *REG4*, scattered cells showed positivity and were identified as serotonin-positive enteroendocrine cells. All IBD samples and PC samples showed signs of Paneth cell metaplasia as defined by DEFA6-positive cells in the crypt base. Figure 1 displays a selection of serial sections stained by IHC for DEFA6 and serotonin, with parallel ISH for *REG1A*, *REG1B*, *REG3A* and *REG4*.

Table 2 LOG2 of expression values for *REG* family genes as measured in microarray analysis described in Granlund et al. (2011). Background level in the full microarray gene expression analysis was approximately 5.5 (N normal mucosa from healthy individual, UCU

un-inflamed mucosa from hepatic flexure of UC patient, CDU un-inflamed mucosa from hepatic flexure in CD patient, UC inflamed colonic mucosa from UC patient, CD inflamed colonic mucosa from CD patient)

Diagnosis (sample number)	<i>REG1A</i>	<i>REG1B</i>	<i>REG3A</i>	<i>REG4</i>
N (205 F)	5.45	5.58	5.31	7.42
UCU (147 F)	12.27	12.87	14.03	10.11
CDU (212 F)	7.99	8.02	11.64	8.60
UC (122 S)	12.69	13.19	10.89	12.78
CD (212 S)	13.80	13.69	13.98	13.14




Fig. 1 Serial sections of colonic biopsy samples for in situ hybridisation (ISH) of *REGs* (a–e) with corresponding immunohistochemistry (IHC) for cell-type markers DEFA6 (e–g) and serotonin (h).

Metaplastic Paneth cell (arrows in a–c, e–g). Enteroendocrine cell (arrows in d, h) Bar 30 μ m. Sections a–c and e–g from un-inflamed ulcerative colitis. Sections d and h from pseudomembranous colitis

The results from ISH of *REG1A*, *REG1B*, *REG3A* and *REG4* in IBD samples are given in Fig. 2. During inflammation, the expression of all REGs increased. *REG1A*, *REG1B* and *REG3A* expression expanded upwards from the crypt base, whereas *REG4* expression was higher towards the luminal end of the crypts, often with no expression in the lower third. During inflammation, all REGs appeared to be expressed by both absorptive colonocytes and goblet cells. The expansion of *REG1B* and to some degree of *REG3A* mRNA expression during inflammation, seemed limited compared with that for *REG1A*, rarely stretching much beyond the bottom third of the crypts. *REG1A* mRNA, on the other hand, could in some instances be found up to almost the luminal face, although the expression was limited to the lower half in most crypts. In un-inflamed samples, epithelial *REG1A* expression seemed to be limited to selected crypts. By closely inspecting serial sections, one could observe a correlation between the presence of Paneth cells and epithelial REG expression; a typical example is shown in Fig. 3. In some crypts of un-inflamed IBD mucosa and in all inflamed samples, *REG4* expression was apparent in epithelial cells. The expression was strongest towards the luminal face of the sections. *REG4* positivity was also seen in scattered enteroendocrine cells in samples with no *REG4* positivity in epithelial cells. Figure 4 presents serial sections displaying these cells, demonstrating serotonin positive enteroendocrine cells expressing *REG4*.

A comparison of *REG1A*, *REG3A* and *REG4* gene expression (as shown by ISH) and REG protein expression (as shown by IHC) in PC is given in Fig. 5. We found a good correlation between the extent of gene expression and protein expression. The sections used in Fig. 5 are subsequent sections, not serial sections as used in Fig. 1, resulting in poorer overlap between sections. The gene expression

pattern for *REG1A*, *REG3A* and *REG4* was similar to that seen in the IBD samples (results not shown).

Discussion

The colon mucosa is a rapidly renewing cell population with most cells undergoing a pattern of crypt-base proliferation, migration towards the lumen during differentiation and then apoptosis and shedding on the luminal surface within 1–2 weeks. In IBD colonic mucosa, crypt elongation is often observed, with an increase in both proliferation and apoptosis (Arai et al. 1999). In addition to the general morphological change with leucocyte infiltration being found in IBD, a change occurs in the cellular composition of the IBD colonic mucosa with, for example, Paneth cell metaplasia being seen in both the inflamed and un-inflamed IBD colon (Haapamäki et al. 1997; Lala et al. 2003). Changes also take place in the number and function of serotonin-positive enteroendocrine cells in the inflamed mucosa (Lomax et al. 2006). Our analysis shows that metaplastic Paneth cells in both un-inflamed samples from IBD patients and in inflamed colonic mucosa express *REG1A*, *REG1B* and *REG3A* mRNA. The main role of Paneth cells in their normal localisation, the mucosa of the small bowel, is to maintain homeostasis by controlling small intestinal microbial load through the secretion of antimicrobial peptides (Bevins and Salzman 2011). The function of metaplastic Paneth cells in the colon is unknown. However, these cells appear in the colon during inflammatory disease and produce a number of antimicrobial peptides such as DEFA6, DEFA5 and REG3A. Thus, the Paneth cells with their antimicrobial peptides probably have a disease-modifying action in colonic inflammation (Cunliffe et al. 2001; Shen et




Fig. 2 ISH of all human *REGs* in colonic inflammatory bowel disease tissue. Sections are taken from samples representing un-inflamed ulcerative colitis (**a–d**), un-inflamed Crohn's disease (**e–h**), inflamed


ulcerative colitis (**i–l**) and inflamed Crohn's disease (**m–p**). ISH was performed with probes for *REG1A*, *REG1B*, *REG3A* and *REG4*. Sample details are given Table 1. Bar 100 μ m

al. 2005). Interestingly, Cunliffe et al. (2001) have shown a similar expression pattern for DEFA5 as is seen for DEFA6, REG1B and REG3A in the present work. Of these peptides, all but REG1B have previously been demonstrated to have an antibacterial effect. Given the similarity in the sequences of REG1B and REG3A and given that their expression patterns are comparable to known antibacterial peptides

such as DEFA5/6, we consider that REG1B is a good candidate for the screening of possible antimicrobial effects.

Good cell-for-cell overlap occurs between DEFA6 and *REG1B/REG3A* expression, with *REG1B/REG3A* being expressed only in the crypt base and in scattered epithelial cells of the lower crypts. *REG1A* shows a similar expression pattern in un-inflamed mucosa but its expression expands to

Fig. 3 Serial sections of a sample of un-inflamed mucosa from the hepatic flexure of a patient with ulcerative colitis. DEFA6 is detected by IHC (**a**) and *REG1A* by ISH (**b**). A clear overlap is seen between crypts containing DEFA6-positive Paneth cells and *REG1A* positivity. Bar 200 μ m






Fig. 4 Serial sections of a sample of un-inflamed mucosa from the hepatic flexure of a patient with Crohn's disease. IHC for serotonin (a) and ISH for *REG4* (b) and *CgA* (c) expression (*CGA* chromogranin A).

A clear overlap of expression can be seen for all three markers, with the number of positive cells being highest for *CgA* and the lowest for *REG4*


almost all cells in the lower half of the colonic crypts during inflammation. This result is similar to that of an earlier study of *REG1A* expression by Shinozaki et al. (2001). The *REG1A* expression pattern suggests that newly proliferated epithelial cells have *REG1A* expression capacity but that they lose this capability during differentiation. This could be an effect of paracrine stimulation, whereby a signal conveyed by basal crypt cells weakens towards the lumen. This paracrine stimulation could originate in Paneth cells, based on the observation that DEFA6-positive cells are always seen in the base of crypts in which *REG1A* expansion to epithelial cells occurs. A Paneth-cell-dependent epithelial expression of *REG* could explain the high expression levels in un-inflamed samples harbouring metaplastic Paneth cells. The reported expression levels of *REG1A/REG1B/REG3A* in healthy small intestine could also be explained by such a mode of induction, as Paneth cells are present in healthy small bowel (Parikh et al. 2012). However, we have as yet been unable to demonstrate such a correlation unequivocally.

REG4 mRNA shows a localisation that is completely different from that of the other *REGs*, with expression only in scattered cells in normal mucosa, expanding to colonocytes of the upper colonic crypts during inflammation and in some un-inflamed IBD samples. The area of positive staining after expansion to colonocytes suggests that these gain *REG4* expression late in differentiation. The scattered

cells have been identified as enteroendocrine serotonin-producing cells. However, not all serotonin-positive cells are *REG4*-positive. Almost no *CgA*-positive/*REG4*-positive/serotonin-negative cells have been seen, suggesting that only the serotonin-positive subgroup of enteroendocrine cells expresses *REG4* in un-inflamed mucosa. However, as several serotoninpositive/*REG4*-negative cells have been observed, the full nature of *REG4* expression in enteroendocrine cells has not been elucidated. As reported earlier, IHC shows *REG4*-positive staining of the mucus excreted from goblet cells during inflammation (Granlund et al. 2011). This clearly indicates a secretory function for this protein. Earlier studies have suggested both a mitogenic and migratory effect of *REG4* on colon cancer cell lines (Rafa et al. 2010). The latter observation could correlate with the expression pattern seen in the present study, with an expression gradient increasing towards the lumen, possibly stimulating colonocytes migration towards the luminal face after proliferation in the crypt base. However, little evidence supports such an effect of *REG4* in non-neoplastic disease and hence further research is needed to identify the role of *REG4* in the setting up of epithelial inflammation.

In conclusion, the expression pattern of *REG* family genes can be divided into at least two groups. *REG1A*, *REG1B* and *REG3* show an apparently Paneth-cell-

Fig. 5 Sequential sections showing overlap of the extent of *REG* mRNA and protein expression in pseudomembranous colitis. ISH/IHC was performed for *REG1A* (a/d), *REG3A* (b/e) and *REG4* (c/f). No suitable protein antibody was found for *REG1B*. Bar 100 μ m



dependent expansion from the colonic crypts during inflammation, whereas *REG4* is expressed in serotonin-producing enteroendocrine cells and expands to epithelial cells of the upper colonic crypts during inflammation. A similar expression pattern is also seen in non-IBD colonic inflammation, as represented by PC. The expression pattern of *REG1A* and *REG1B*, seen together with sequence similarities with *REG3A*, suggests that these peptides are good candidates for the screening of antimicrobial effects.

Open Access This article is distributed under the terms of the Creative Commons Attribution License, which permits any use, distribution and reproduction in any medium, provided the original author(s) and the source are credited.

References

- Arai N, Mitomi H, Ohtani Y, Igarashi M, Kakita A, Okayasu I (1999) Enhanced epithelial cell turnover associated with p53 accumulation and high p21WAF1/CIP1 expression in ulcerative colitis. *Mod Pathol* 12:604–611
- Astrosini C, Roefzaad C, Dai Y-Y, Dieckgraefe BK, Jöns T, Kemmner W (2008) *REG1A* expression is a prognostic marker in colorectal cancer and associated with peritoneal carcinomatosis. *Int J Cancer* 123:409–413
- Bevins CL, Salzman NH (2011) Paneth cells, antimicrobial peptides and maintenance of intestinal homeostasis. *Nat Rev Microbiol* 9:356–368
- Cash HL, Whitham CV, Behrendt CL, Hooper LV (2006) Symbiotic bacteria direct expression of an intestinal bactericidal lectin. *Science* 313:1126–1130
- Cunliffe RN, Rose FRAJ, Keyte J, Abberley L, Chan WC, Mahida YR (2001) Human defensin 5 is stored in precursor form in normal Paneth cells and is expressed by some villous epithelial cells and by metaplastic Paneth cells in the colon in inflammatory bowel disease. *Gut* 48:176–185
- Dieckgraefe BK, Crimmins DL, Landt V, Houchen C, Anant S, Porche-Sorbet R, Ladenson JH (2002) Expression of the regenerating gene family in inflammatory bowel disease mucosa: *Reg I[alpha]* upregulation, processing, and antiapoptotic activity. *J Invest Med* 50:421–434
- Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge YC, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smyth G, Tierney L, Yang JYH, Zhang JH (2004) Bioconductor: open software development for computational biology and bioinformatics. *Genome Biol* 5:16
- Granlund AVB, Beisvag V, Torp SH, Flatberg A, Kleiveland PM, Østvik AE, Waldum HL, Sandvik AK (2011) Activation of *REG* family proteins in colitis. *Scand J Gastroenterol* 46:1316–1323
- Guo Y, Xu J, Li N, Gao F, Huang P (2010) *RegIV* potentiates colorectal carcinoma cell migration and invasion via its CRD domain. *Cancer Genet Cytogenet* 199:38–44
- Haapamäki MM, Grönroos JM, Nurmi H, Alanen K, Kallajoki M, Nevalainen TJ (1997) Gene expression of group II phospholipase A2 in intestine in ulcerative colitis. *Gut* 40:95–101
- Heiskala K, Giles-Komar J, Heiskala M, Andersson L (2006) High expression of *RELP* (*Reg IV*) in neoplastic goblet cells of appendiceal mucinous cystadenoma and pseudomyxoma peritonei. *Virchows Arch* 448:295–300
- Lala S, Ogura Y, Osborne C, Hor SY, Bromfield A, Davies S, Ogunbiyi O, Nuñez G, Keshav S (2003) Crohn's disease and the *NOD2* gene: a role for Paneth cells. *Gastroenterology* 125:47–57
- Lawrance IC, Fiocchi C, Chakravarti S (2001) Ulcerative colitis and Crohn's disease: distinctive gene expression profiles and novel susceptibility candidate genes. *Hum Mol Genet* 10:445–456
- Loftus EV Jr (2004) Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. *Gastroenterology* 126:1504–1517
- Lomax AE, Linden DR, Mawe GM, Sharkey KA (2006) Effects of gastrointestinal inflammation on enteroendocrine cells and enteric neural reflex circuits. *Auton Neurosci* 126–127:250–257
- Oue N, Mitani Y, Aung PP, Sakakura C, Takeshima Y, Kaneko M, Noguchi T, Nakayama H, Yasui W (2005) Expression and localization of *Reg IV* in human neoplastic and non-neoplastic tissues: *Reg IV* expression is associated with intestinal and neuroendocrine differentiation in gastric adenocarcinoma. *J Pathol* 207:185–198
- Oue N, Kuniyasu H, Noguchi T, Sentani K, Ito M, Tanaka S, Setoyama T, Sakakura C, Natsugoe S, Yasui W (2007) Serum concentration of *Reg IV* in patients with colorectal cancer: overexpression and high serum levels of *Reg IV* are associated with liver metastasis. *Oncology* 72:371–380
- Parikh A, Stephan AF, Tzanakakis ES (2012) Regenerating proteins and their expression, regulation, and signaling. *Biomol Concepts* 3:57–70
- Player AN, Shen LP, Kenny D, Antao VP, Kolberg JA (2001) Single copy gene detection using branched DNA (bDNA) in situ hybridization. *J Histochem Cytochem* 49:603–611
- Rafa L, Dessein AF, Devisme L, Buob D, Truant S, Porchet N, Huet G, Buisine MP, Lesuffleur T (2010) *REG4* acts as a mitogenic, motility and pro invasive factor for colon cancer cells. *Int J Oncol* 36:689–698
- Sekikawa A, Fukui H, Suzuki K, Karibe T, Fujii S, Ichikawa K, Tomita S, Imura J, Shiratori K, Chiba T, Fujimori T (2010) Involvement of the *IL 22/REG I[alpha]* axis in ulcerative colitis. *Lab Invest* 90:496–505
- Shen B, Porter EM, Reynoso E, Shen C, Ghosh D, Connor JT, Drazba J, Rho HK, Gramlich TL, Li R, Ormsby AH, Sy M-S, Ganz T, Bevins CL (2005) Human defensin 5 expression in intestinal metaplasia of the upper gastrointestinal tract. *J Clin Pathol* 58:687–694
- Shinozaki S, Nakamura T, Iimura M, Kato Y, Iizuka B, Kobayashi M, Hayashi N (2001) Upregulation of *Reg 1α* and *GW112* in the epithelium of inflamed colonic mucosa. *Gut* 48:623–629
- Smyth G (2005) Limma: linear models for microarray data. In: Gentleman R, Carey V, Huber W, Irizarry R, Dudoit S (eds) *Bioinformatics and computational biology solutions using R and Bioconductor*. Springer, Berlin, pp 397–420
- Zelensky AN, Gready JE (2005) The C-type lectin-like domain superfamily. *FEBS J* 272:6179–6217
- Zhang YW, Ding LS, Lai MD (2003) *Reg* gene family and human diseases. *World J Gastroenterol* 9:2635–2641